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Summary 
 
Purpose: Electrochemotherapy (ECT) is a therapeutic approach based on the local 
application of electrical pulses that permeabilize cell membranes to enhance the uptake of 
low-permeant chemotherapeutic agents, thus increasing their cytotoxic effects.  
Materials and Methods: Twenty-one patients with SCC of the lower lip were treated 
according to the European Standard Operating Procedures of Electrochemotherapy. 
Bleomycin (15,000 IU/m2 body surface area) was administered intravenously over a 1-minute 
period. Eight electrical pulses (amplitude, 1000 V/cm; duration, 100 µs) were generated and 
delivered at a repetition frequency of 5 kHz. Changes in tumor volume were used to assess 
treatment response. 
Results: Objective response (OR), complete response (CR), and partial response (PR) rates of 
100%, 71.4%, and 28.6% respectively were demonstrated following a single session of ECT. 
ECT was well tolerated, and no adverse events occurred.  
Conclusions: Intravenous bleomycin-based ECT is a safe and effective therapy for SCC of 
the lower lip. ECT improves the quality-of-life of patients by preserving the function and the 
aesthetic appearance of the affected area. ECT provides a therapeutic option for elderly and 
frail patients who, due to their state of health, are not suitable for, or refuse surgical 
interventions.  
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
INTRODUCTION 
Squamous cell carcinoma (SCC) is the second most common type of skin cancer (Alam M, 
Ratner D, 2001). The incidence of cutaneous SCC has increased over the last 15 years, 
possibly as a consequence of the ageing population and improvements in our ability to detect 
skin cancer at an early stage (Glass AG, Hoover RN. 1989; Motley R et al. 2002; 
4. Rogers HW et al. 2006). 
Cancer of the lip is the most common malignant lesion of the oral cavity, and 
approximately 90–93% of these are SCCs (Zitsch RP 3rd et al. 1995, Pohl MJ et al. 2000) 
Although considered the gold standard treatment option, radical surgery is sometimes 
unsuitable for patients due to their poor performance status or a refusal of surgery for 
personal, cosmetic and functional sequelae, or for fear of requiring additional and more 
radical surgical intervention. 
Radiotherapy is also an effective treatment option for SCC of the lower lip, with 
comparable outcomes to surgical interventions for early staged cancers (Mali B et al, 2013). 
Despite radiotherapy being offerred as a primary treatment option, there may be a group of 
patients who are unwilling to undergo multi-staged procedures, particularly those who live in 
rural areas and as a result find travelling to hospitals with adequate radiotherapy services a 
challenge. 
Several clinical studies propose electrochemotherapy (ECT) as a novel, complementary 
therapeutic tool to control cutaneous and subcutaneous tumors with a well-tolerated drug 
delivery system (Mali B et al. 2013). Chemotherapeutic drugs with low-permeability but high 
cytotoxicity (e.g. bleomycin and cisplatin) are administered. Following this, a series of 
electrical pulses into the solid tumor are applied. This enhances the uptake of 
chemotherapeutic agents into cells and hence increases the cytotoxic effect to the cells (Mir 
LM et al. 1991; Jaroszeski MJ et al. 2000; Mir LM, 2001).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Our research group has previously reported the effectiveness of ECT in the treatment of non-
melanoma head and neck cutaneous and subcutaneous tumors (Gargiulo M et al. 2010; 
Gargiulo M et al, 2012). With this study, we pursued further investigation into the use of ECT 
for patients with SCC of the lower lip without evidence of cervical lymphadenopathy. We 
aimed to evaluate the antitumor efficacy of systemic bleomycin-based ECT in patients with 
SCC of the lower lip, with a long-term follow-up period.  
 
MATERIALS AND METHODS 
Patient selection  
Between May 2009 and September 2015, 75 patients suffered lower lip SCC; amongst 
these, 21 patients with SCC of the lower lip were treated with ECT in the Maxillo-Facial 
Department of Antonio Cardarelli Hospital in Naples.  
An electronic database was designed. It contained pre-, intra-, and post-ECT outcomes 
which were collected retrospectively. Written informed consent was obtained from each 
patient prior to treatment provision. Our inclusion criteria are as follows: patients with 
biopsy-confirmed SCC of the lower lip, patients with an estimated life expectancy of greater 
than 6 months; measurable cutaneous or mucosal tumor lesions. Patients were offered ECT as 
a therapeutic, palliative or neoadjuvant option based upon their current health status or due to 
their refusal of surgery. Recorded patient characteristics include poor general health, 
advanced age, cardiac disease not attributable to electrocardiac malfunction, reduced lung 
performance, medical comorbidities, and an unsutiability for a radical surgical intervention. 
Exclusion criteria included clinically manifesting cardiac arrhythmias or those with an in-situ 
pacemaker, interstitial lung fibrosis, epilepsy, an active infection, a past history of bleomycin 
hypersensitivity, kidney failure, previous treatment with bleomycin at the maximum 
cumulative dosage, and different anticancer therapies administered within 2 weeks of the ECT 
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(Mir LM et al. 2006; Campana LG et al. 2009 ; Gargiulo M et al. 2010) . Non-surgical 
patients were defined as those with one or more of the following characteristics: poor 
performance status, age greater than 85 years, cardiac deficit not related to electrical 
malfunction, reduced lung performance, co-morbidities preventing the use of a general 
anaesthesia, or those patients requiring a radical surgical procedure that they were unfit to 
undergo. Seven out of 21 patients had been included in our previous article (Gargiulo M et al. 
2012). For each patient, the tumor size was measured using two perpendicular diameters with 
a caliper, and photographs were taken prior to any intervention. Computed tomography (CT) 
was used to determine the stage of the tumour according to the tumour, node and metastasis 
(TNM) classification. ECT and patient selection were based on the European Standard 
Operating Procedures of Electrochemotherapy (ESOPE) guidelines (Mir LM et al. 2006).  
 
In this study, ECT was provided for a range of indications (Table1): 
1. Therapeutic treatment in non-surgical patients. 
2. Patients who previously underwent surgery but experienced tumour recurrence. 
3. Neo-adjuvant treatment to reduce the tumor size before surgical intervention. 
4. Palliative treatment, for symptomatic relief.  
5. Patients who declined surgical intervention. 
6. Patients who declined primary radiotherapy. 
 
Before providing ECT, all patients had been fully informed of the specific details of 
their disease, about the ECT procedure and its potential risks. All patients provided written 
informed consent prior to treatment.  
 
Electrochemotherapy treatment 
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Patients were treated under sedation with midazolam and remifentanil, and local 
anesthesia (2% lidocaine) was administered via a 1- to 5-mL peritumoral injection. N20 4B 
electrodes (IGEA S.p.A., Carpi, Italy) with linear array needles were used in all cases. 
Electrodes were inserted deep into the tumor and perilesional area (1-cm margins) to secure 
the tumor and its margins within the electrical field generated. An intravenous bolus dose 
(15,000 IU/m2 body surface area) of bleomycin was injected over a 1-minute period. Eight 
electrical pulses (amplitude, 1000 V/cm; duration, 100 µs) were generated and delivered at a 
repetition frequency of 5 kHz using the Cliniporator device (IGEA S.p.A., Carpi, Italy) with 
hexagonal electrodes. To ensure homogeneous distribution of the drug into the tumor volume, 
pulses were delivered from 8 to 28 minutes after the intravenous injection (Mir LM et al. 
2006; Sersa G. 2006).  
 
Response assessment and follow-up. 
Through measuring changes in tumor volume, the treatment response was evaluated, 
in accordance with the World Health Organization (WHO) guidelines (WHO, 1997). 
Treatment response was evaluated 6 weeks after the administration of ECT and was classified 
as follows: “Objective response” (OR), defined as any decrease in tumour volume, which was 
further subdivided into “complete response” (CR), when the tumor was not palpable; and 
“partial response” (PR), a decrease in tumor volume by >50%. “No change” was defined as 
an increase in tumor size of <25% or a decrease of <50% in tumor volume, and finally 
“progressive disease” if the tumor volume increased by ≥25%.  
Patients were followed-up weekly for the first 6 weeks, and then at monthly intervals. Tumors 
size was measured, and photographs were taken at each follow-up appointment. 
In our analysis, we describe the follow-up period at three separate time points: 6 
weeks, 18 months, and the patients’ last-follow up appointment. (Table 3) 
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Statistical analysis 
IBM SPSS statistics version 24 software was used for data analysis. Categorical 
variables are presented as frequencies and percentages. Follow-up length is positively skewed 
and is presented as a median and interquartile range (IQR), whereas age is normally 
distributed and is presented as means and standard deviation (SD). Outcome frequencies were 
calculated using basic descriptive statistics. 
 
RESULTS 
Patient demographics 
Between May 2009 and September 2015, a total of 21 patients with SCC of the lower 
lip underwent ECT; 12 were male (57.1%) and 9 were female (42.9%). The mean age was 
76.0 years (SD ±8.70) with a range from 60.0 to 91.0 years (Table 1). Non-cancerous 
respiratory disease constituted patients with a diagnosis of chronic obstructive pulmonary 
disease (n=3) or an inadequate respiratory function to undergo surgical intervention (n=1) as 
assessed by an independent physician. “Significant cardiovascular disease” included one, or a 
combination, of the following: a past medical history of ST elevated myocardial infarction 
(n=1), non−ST elevated myocardial infarction (n=2), coronary artery bypass surgery (n=1), 
stroke (n=1), current severe aortic stenosis (n=1) or bilateral carotid artery stenosis (n=1) 
(Table 2). 
In all, 76.2% (n=16/21) of patients were treated with therapeutic intent. Five 
underwent ECT due to the recurrence of a previous SCC at the same location. Neo-adjuvant 
ECT was provided to 9.5% (2/21) of patients prior to surgery; one who had no history of 
previous skin cancer affecting the lip, and one who had a recurrence. Palliation was the 
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treatment intention in 14.3% (3/21) of patients. A refusal of surgery by the patient influenced 
the decision to perform ECT in 23.8% (5/21) of participants (Table 1). 
 
Treatment response 
Six weeks following ECT, an objective response (OR) was achieved in 100% of 
patients (21/21). In all, 71.4% (15/21) of patients experienced a CR and 28.6% (6/21) 
experienced a PR. No tumors showed disease progression. 
After the first cycle of ECT, recurrence of the tumour was identified in 14.3% (3/21) 
participants. Of those who experienced recurrence, two occurred at 12 months post-ECT and 
one after 18 months. One patient (patient No. 3), refused additional treatment. This patient has 
been monitored for 49 months following the recurrence and remains in a clinically stable state 
with no evidence of disease progression. The other two patients (No. 9 and No. 17) underwent 
surgical resection of the tumour; no recurrence has been identified in either patient since.  
Of the patient population undergoing ECT, 28.6% (6/21) required additional therapy. 
One patient required further surgery after only a PR was achieved and the tumour recurred at 
12-months’ follow-up (patient No. 17). In addition, surgery was indicated after an initial CR 
but with subsequent recurrence 18-months following ECT for one patient (patient No.12), a 
second course of ECT was provided following a partial response in two patients (patient No.5 
and No.9), and finally two patients received a neo-adjuvant course of ECT following a PR to 
the first course of ECT (patient No. 2 and 6) (Table 3). Additional treatment was successful in 
all cases. No patients experienced further recurrence following these additional interventions. 
 
Follow-up and response duration (Table 3) 
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Median follow-up length was 27 months, ranging from 18 to 74 months, with the 25th 
and 75th percentile equating to 21 and 49 months respectively. One patient was lost to follow-
up 18 month post-ECT (patient No. 18). 
At 18-month follow-up, 85.7% (18/21) patients were stable with no recurrent disease. 
9.5% (2/21) experienced a recurrence of the disease: one patient refused any additional 
treatment and the other, whose recurrence did not occur until 18 months post-ECT, was 
successfully treated by surgery. One patient deceased due to an unrelated cause after 18 
months’ follow-up. 
Three patients have died from an unrelated cause; these patients were followed up for 
36, 30 and 18 months respectively post-ECT, and all showed no evidence of disease 
recurrence at the time of death. Of those alive (n=18), 94.4% (17/18) patients were well with 
no evidence of recurrent disease. Patient No. 3 experienced disease recurrence. He underwent 
surgical excision of the tumour with primary closure of the defect. After surgery the disease 
remained stable with no evidence of disease progression. At the last follow-up appointment, 
no instances of delayed wound healing, infection, or other minor complications were 
identified. 
 
Toxicity and Other Side Effects 
There was no evidence of serious ECT-related adverse effects or bleomycin-related 
hematologic toxicity observed in any patients. Mild erythema, limited to the tumor and 
surrounding tissue, appeared in 19.0% (4/21) patients after ECT. During the ECT, patients 
reported an unpleasant sensation due to muscle contractions associated with the electrical 
pulses. Some patients reported localized minor discomfort following treatment. Post-ECT 
pain was successfully managed with simple oral analgesia.  
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DISCUSSION 
ECT is a key topic in surgical oncology. Both pre-clinical and clinical trials have 
proved its efficacy in many different tumor types that are inoperable and/or refractory to 
chemotherapy and radiotherapy. The antitumoral efficacy of ECT in vitro and in vivo is due to 
a dual mechanism involving cell apoptosis and tissue ischemia (Cemazar M et al, 2001; Mir 
L. 2006). The immunological-based mechanism of ECT-mediated anti-tumoral effects is 
under debate (Mir LM et al. 1992; Sersa G et al.1997; Mir LM, Orlowski S, 1999; Quaglino P 
et al. 2008). ECT-induced apoptosis has been associated with aberrant mitosis (Mir L. 2006). 
Within 5 minutes of applying ECT, all mitoses in the tumor are aberrant. During the 24 hours 
following ECT, the cells initiate repair mechanisms with mitotic division. Caspase 
3−dependent atypical mitosis and a large-scale infiltration of macrophages and dendritic cells 
are observed, indicating tumor cell apoptosis. Experimental studies using Patent blue suggest 
that ECT induces ischemic necrosis of tumor cells with an anti-vascular mechanism; this is 
particularly useful in controlling the symptoms of bleeding nodules (Möller MG, et al, 2011). 
In contrast to other physical ablation technologies, ECT does not denature collagenic 
extracellular matrix proteins (Mir LM, et al, 1992;WHO,1997 ; Sersa Get al 1997; Mir LM, 
Orlowski S, 1999; Cemazar M, et al. 2001; Mir LM, et al, 2006; Sersa G. 2006 ; Mir L. 2006; 
Quaglino P et al. 2008; Snoj M, et al. 2009; Campana LG et al. 2009). To date, all studies of 
cisplatin and bleomycin-based ECT demonstrate a low toxicity profile for the 
chemotherapeutic agents, with minimal systemic side effects (Bloom DC, Goldfarb PM. 
2005; Mir LM, et al. 2006; Punglia RS et al. 2007; Fantini F et al. 2008; Campana LG et al. 
2009;  Matthiessen LWet al. 2011; Muñoz MV, Ortega PG. 2011; Möller MG et al. 
2011;Testori A et al. 2012 ; Campana LG, et al. 2012; Sersa G et al. 2012;  Kis E et al. 2012; 
Mevio N et al. 2012; Curatolo P et al. 2012; Bonadies A et al. 2015; Rotunno R et al. 2016.).  
We did not observe any major complications in our study either. Although some patients 
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reported discomfort during the application of electric pulses, the treatment was well tolerated 
with the administration of local anesthesia. Therefore, it is advisable to use an ECT repetition 
frequency of 5 kHz rather than 1 kHz, as this reduced the time required to perform the 
treatment, which is particularly helpful when multiple lesions need to be treated during the 
same session. Furthermore, each electric pulse at 5 kHz generates a single contraction of the 
muscle underlying the area to be treated, rather than the eight contractions during a 1-minute 
period when a 1-kHz frequency is used.  
In 2006, ESOPE showed that ECT is a valuable treatment option for up to of 80% of 
cutaneous and subcutaneous metastatic nodules (Mir LM et al 2006). Recent clinical studies 
applying the ESOPE guidelines have corroborated the effectiveness of ECT for melanoma 
(Quaglino P et al. 2008; Snoj M, et al. 2009; Campana LG et al. 2009; Matthiessen LW et al. 
2011; Muñoz MV, Ortega PG. 2011; Möller MG et al. 2011;Testori A et al. 2012 ; Campana 
LG, et al. 2012) and breast cancer metastases involving the chest wall (Bloom DC, Goldfarb 
PM. 2005; Punglia RS et al. 2007; Campana LG et al. 2009, Muñoz MV, Ortega PG. 2011; 
Sersa G et al. 2012), primary skin tumors (Bloom DC, Goldfarb PM 2005; Gargiulo M et al. 
2010; Gargiulo M et al, 2012; Fantini F et al. 2008; Kis E et al. 2012; Mevio N et al. 2012), 
and Kaposi’s sarcoma (Rotunno R et al. 2016) . Our study has demonstrated that ECT is 
effective at treating non-melanoma head and neck cutaneous and subcutaneous tumors 
(Gargiulo M et al. 2010; Gargiulo M et al, 2012). ECT has been successfully used for the 
treatment of a rare cancer in a cosmetically sensitive area, such as the orbital margin (Statigos 
A et al 2015). A recent multicenter prospective non-randomized phase II trial involving a 
sample size of 55 patients with head and neck cancers confirmed ECT’s effectiveness in 
providing local disease control with good functional and cosmetic outcomes. ECT has been 
proposed as a first-line treatment of head and neck cancers (Rotunno R et al. 2016).  
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The route of administration for the chemotherapy used in ECT has previously been under 
investigation. Two types of chemotherapy are typically used to treat mucosal head and neck 
cancers with ECT: bleomycin or cisplatin (Statigos A et al. 2015). Similarly there has been 
debate concerning whether the route by which the chemotherapy is administered affects 
treatment efficacy. The ESOPE guidelines advise that bleomycin should be administered 
using the intravenous (IV) route rather than intratumourally. As part of the ESOPE study, 
Marty et al (Marty G et al. 2006) demonstrated bleomycin’s superiority over cisplatin for the 
treat of cutaneous and subcutaneous tumour nodules in patients with skin malignancies. 
Similarly, this study demonstrates that IV bleomycin is more effective than intratumoural, 
highlighted by the local tumour control rate of 88% using the IV route, compared with 73% 
when administered intratumourally. Most research using bleomycin ECT predominantly uses 
the IV route. Plaschke et al describe their EURECA project (Plaschke CC et al. 2017 ). In this 
study, 95% of their patient cohort received IV bleomycin. As a consequence of the current 
evidence, we therefore replicated the methodology of previous studies and provided 
bleomycin to our patients using the IV route. 
The treatment of primary and recurrent SCCs of the lower lip in patients considered to 
be unfit for surgery remains a challenge for surgeons. In the present study, we obtained OR 
and CR rates of 100% and 71.4% respectively in 21 patients with SCC of the lower lip treated 
with a single ECT session according to the ESOPE guidelines. In our sample population, 
three patients underwent ECT with palliative intent, all of whom had evidence of 
lymphadenopathy and stage T3N1M0 cancer. One patient received ECT as neoadjuvant 
treatment, who had stage T4aN1M0 cancer. Rather unique to our sample population, we had 
five patients who refused surgery (four staged T1N0M0 and one staged T2N0M0) and 
subsequently received ECT therapy. In those five patients, a stable CR was achieved 
following a single ECT session throughout their follow-up period (55, 27, 21, 18 and 18 
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months). Four patients underwent a second course of ECT, two of whom received a second 
ECT session as neoadjuvant therapy at the time of surgery. Two additional patients underwent 
surgery-only following the first course of ECT.  
In the present study, ECT proved to be a reliable neo-adjuvant therapy in patients with 
stage T3 SCC of the lower lip; higher response rates were achieved in T1-T2 tumors. The 
results of our study support those presented in previous studies (Bertino G et al 2016). 
When evaluating the treatment response in patients with SCC, it is important to also 
calculate the rate of recurrences. Our study monitored all patients for 18 months or more post-
ECT.  Median follow-up length was 27 months, which ranged from 18 to 74 months. This 
length of follow-up shows the long-term efficacy of the ECT treatment for lower lip SCC and, 
to our knowledge, this is the longest follow-up period shown in the current literature. In our 
cohort, three patients presented with recurrent disease. The new lesions were diagnosed 
promptly and surgically treated under local anesthesia in two patients. However, one patient 
refused additional treatment. 
Owing to the radio-responsive nature of SCCs, radiotherapy is a valid first-line treatment 
option for patients with early-stage N0 lip SCC (De Visscher JG, et al. 1998; Vukadinovic M 
et al. 2007). Radiotherapy may be considered a particularly attractive option for elderly 
patients; it reduces the requirement for general anaesthesia, surgical interventions or 
hospitalization. However, radiotherapy does have some disadvantages which may hinder its 
uptake by patients. The most common disadvantages include a patient’s delayed wound 
healing, cutaneous desquamation and buccal mucositis which can take 3 to 4 weeks to heal. In 
addition, post-treatment complete tumour regression typically takes longer, and early biopsies 
may not demonstrate tumour recurrence due to atypical fibroblasts induced by radiotherapy, 
which can result in poorer outcomes if recurrences do occur. Finally, osteonecrosis of the jaw 
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is a potential radiotherapy-related complication in elderly patients and is associated with 
substantial treatment-induced morbidity (Thanh Pham T et al. 2015; Lai TY et al 2017). 
SCC of the lower lip likely affects quality of life to a substantial degree owing to the 
functional and cosmetic importance of the lips in daily life. In our patient sample, no delayed 
wound healing or infections occurred. All lesions treated with ECT healed without any 
noticeable asymmetry or keloid scar formation. In particular, we noticed that the healing 
occurred by secondary intention which helped to maintain the continence of the mouth 
because of tangential scar retractions (Fig 1) However, evidence has shown that in patients 
will full thickness lesions, wide loss of tissue with fistula formation or labial incompetence 
can occur (Bertino G et al 2016). An excellent functional and cosmetic result can be 
appreciated following ECT, even for large tumors that otherwise would have required 
extensive surgery with total lip excision and free tissue transfer to reconstruct the defect (Fig 
2). Unfortunately, we did not formally assess the functional and cosmetic result with any 
validated questionnaire. All patients were treated under local anaesthetic with or without 
sedation. This demonstrates an opportunity to offer an effective and validated treatment 
option for patients who cannot or are not willing to undergo surgical excision under general 
anaesthesia. This treatment improves the quality of life of patients with SCC of the lower lip, 
not only by conserving the anatomical integrity of the lips, but by minimizing pain and 
allowing patients to return to their normal activities (Bertino G et al 2016) (Fig 3).  
  
CONCLUSION 
Intravenous bleomycin-based ECT is a safe, time-efficient and effective therapeutic 
approach for the treatment of SCC of the lower lip. According to our findings, its main 
indication is for stage T1 and T2 tumors without detectable lymphadenopathy. The procedure 
causes no local disfigurement, nor does it alter the function of the lips. ECT preserves the 
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function and aesthetic appearance of the mouth. Furthermore, patients can immediately 
resume their daily activities after treatment. ECT is easy to perform, the learning curve is 
short, and the costs are reasonable, although a comprehensive cost−benefit analysis is needed 
to compare ECT’s cost-effectiveness versus surgery. An observational study may be needed 
to directly compare the clinical outcomes of surgery versus ECT to treat SCC of the lower lip, 
which would help to determine the patient sub-group that would gain the most benefit from 
ECT as a first-line treatment for lower lip SCC. 
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Figure 1. (A) Patient No. 4, an 86-year-old woman. Lower lip squamocellular carcinoma 
T2N0M0. The patient refused surgery and was treated with therapeutic intent. (B) An 
intraoperative image displaying an example of one ECT session in this patient. (C) Stable 
result achieved post-ECT. Image was taken 55 months follow-up. A complete response was 
achieved at 6 weeks post-ECT, and disease remains stable.  
 
Figure 2. (A) Patient No. 11, an 83-year-old man. Lower lip squamocellular carcinoma 
T2N0M0. Indicated for ECT following disease recurrence post-surgery. Treatment was 
performed with therapeutic intent. (B) An intraoperative image displaying one ECT session. 
(C) Image obtained 27 months post-ECT. A complete response was achieved 7 weeks post-
ECT, and disease remains stable.  
 
Figure 3. (A) Patient No. 13, a 60-year-old man. Lower lip squamocellular carcinoma 
T2N0M0. ECT was performed with therapeutic intent. (B) An intraoperative image of one 
ECT session. (C) Outcomes 21 months post-ECT. A complete response was achieved at 6 
weeks, and disease remains stable.  
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Table 1.  Baseline demographics, TNM staging, and treatment intent 
Patient 
No 
Age 
(years) 
Sex (M/F) Tumour 
type 
(recurrent) 
TNM 
staging 
Comorbidities Treatment 
intent 
 
1 71 M SCC T2N0M0 Previous lung cancer  T 
2 84 F SCC T2N0M0 T2DM, Hypertension  N 
3 80 M SCC T2N0M0 Hypertension, Cardiac by-
pass 8 months prior 
T 
4 86 F SCC T2N0M0 Hypertension  RS + T 
5 77 M SCC T3N1M0 None P 
6 68 M SCC (R) T4aN1M
0 
T2DM, Hypertension, 
Stroke  
N 
7 91 F SCC T1N0M0 Emphysema, Severe aortic 
stenosis 
T 
8 71 F SCC(R) T2N0M0 T2DM, Hypertension  T 
9 86 M SCC T2N0M0 Reduced lung performance P 
10 68 F SCC T1N0M0 T2DM, Hypertension  RS + T 
11 83 M SCC (R) T2N0M0 None T 
12 74 M SCC (R) T2N0M0  COPD, Hypertension T 
13 60 M SCC T1N0M0 Stroke 6 months prior T 
14 65 F SCC T1N0M0  RS + T 
15 83 M SCC T2N0M0 T2DM, Hypertension, 
STEMI 
T 
16 66 F SCC T1N0M0 T2DM, Hypertension , 
NSTEMI, Emphysema 
RS + T 
17 80 M SCC T3N1M0 None P 
18 77 M SCC (R) T2N0M0 Alzheimer’s disease,  
Depression, Hip fracture 
T 
19 66 F SCC T1N0M0 T2DM, Hypertension ,  T 
20 72 F SCC T1N0M0 T2DM, Hypertension , 
NSTEMI  
RS + T 
21 87 M SCC T2N0M0 None T 
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F, female; M, male; SCC: dquamous cell carcinoma; R: recurrent; TNM: yumour, node, 
metastasis; N: neoadjuvant; T: therapeutic; RS: refused surgery; P: palliative; STEMI: ST 
elevated myocardial infarction; NSTEMI: Non−ST elevated myocardial infarction; T2DM: 
type 2 diabetes mellitus. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Patient comorbidities 
Comorbidity No. (%) 
Lung cancer 1/21 (4.8) 
Non-cancerous respiratory disease 3/21 (14.3) 
T2DM 8/21 (38.1) 
HTN 13/21 (61.9) 
Significant cardiovascular disease 7/21 (33.3) 
Frailty 1/21 (4.8) 
Alzheimer’s disease 1/21 (4.8) 
Depression 1/21 (4.8) 
Hip replacement 1/21 (4.8) 
Bowel cancer 1/21 (4.8) 
BrCa 1/21 (4.8) 
BrCa (female cohort) 1/9 (11.1) 
 
T2DM: type 2 diabetes mellitus; HTN: hypertension; BrCa: breast cancer. 
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Table 3. Post-operative outcomes 
 
 
Patient No. ECT 
response 
(6 weeks 
post-therapy) 
Tumour 
recurrence 
following first 
ECT (months 
post-ECT) 
Additional 
Treatment 
required 
Patient status 18-
months post-
therapy 
Follow-up 
(months) 
Patient’s status at 
last follow-up 
appointment 
1 CR N NONE NR 74 NR 
2 PR 
N 
ECT + 
SURGERY NR 
68 
NR 
3 CR Y  
(12) 
NONE R 61 R 
4 CR N NONE NR 55 NR 
5 PR* N  ECT  NR 49 NR 
6 PR 
N 
ECT + 
SURGERY NR 
49 
NR 
7 CR N NONE NR 36 DUC 
8 CR N NONE NR 33 NR 
9 PR* N ECT  NR 30 DUC 
10 CR N NONE NR 27 NR 
11 CR N NONE NR 27 NR 
12 CR Y  
(18) 
SURGERY R† 24 NR 
13 CR N NONE NR 21 NR 
14 CR N NONE NR 21 NR 
15 CR N NONE NR 18 NR 
16 CR N NONE NR 18 NR 
17 PR Y  
(12) 
SURGERY NR† 27 NR 
18 PR N NONE NR LFU NR 
19 CR N NONE NR 21 NR 
20 CR N NONE NR 18 NR 
21 CR N NONE DUC 18 DUC 
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ECT: electrochemotherapy; CR: complete response; PR: partial response; DUC: deceased 
from unrelated cause; N: none; NR; no recurrence; R: recurrence; LFU: lost to follow-up. 
*CR was achieved following second course of ECT. 
†No recurrence following surgery. 
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